The Path to Public Service at SEAS
Should Supreme Court Justices Have Term Limits? That ‘Would Be Fine,’ Breyer Says at Harvard IOP Forum
Harvard Right to Life Hosts Anti-Abortion Event With Students For Life President
Harvard Researchers Debunk Popular Sleep Myths in New Study
Journalists Discuss Trump’s Effect on the GOP at Harvard IOP Forum
The Dean's office late yesterday approved plans of the newly organized Harvard Shakespearian Players to present "The Play's the Thing," selected scenes from five Shakespeare plays.
Although definite plans began to take shape only three days ago, all casting has been done with the exception of a girl to play Juliet in the balcony scene from "Romeo and Juliet," according to Victor N. Claman, producer. All those interested in the part should call TRowbridge 6-7179 by Thursday night, Claman said.
The group has secured permits from the University for the use of the Union Common Room for the performance, which will be presented during the week of August 12, probably on August 14, 15, 16, and 17, according to Claman.
Scenes from "Henry IV, Part I," "Richard II," "Romeo and Juliet," "Macbeth," and "Midsummer Night's Dream" are scheduled. The leading roles will be taken by Eugene Gervasi, Thomas Lumbard, and Erich Segal, all members of the Harvard Dramatic Club.
Claman has produced three other plays, including the current Gilbert and Sullivan operetta "The Gondoliers." All three leading actors in the production have had extensive experience, Claman said.
In "Quo Vadis"
Gervasi has appeared in "Quo Vadis" and "Barefoot Contessa." Segal has appeared in productions at Harvard in French and Greek as well as in English. Lumbard is Director of the New Theater Workshop and has appeared in many Shakespearian productions over the past three years, Claman added.
Gervasi has also danced with the Rome Ballet Opera, and has dubbed several Italian films in English. Segal's most recent role was that of Creon in Harvard's presentation of "Oedipus of Colonus."
Want to keep up with breaking news? Subscribe to our email newsletter.